Korea's EverEx has raised 14.8 billion won ($10.7 million) in a Series B round to accelerate its global expansion and advance its AI-driven motion analysis technology for musculoskeletal care.

The latest funding brings EverEx’s total raised to approximately 25 billion won since its founding in 2017. It follows an 8 billion won Series A round in 2023. 

Premier Partners led the round, with continued participation from QUAD Asset Management and Hana Ventures. New backers include Korea Development Bank, Korea Venture Investment Corp., the Korea SMEs and Startups Agency, and Japan’s SBI Investment.

EverEx plans to use the funds to scale its AI-powered motion analysis and remote rehab monitoring platform, which is already deployed at over 100 hospitals in Korea and abroad. The company is ramping up commercialization of its U.S.-based product, EverEx Rehab, and aims to expand into Asia-Pacific markets including Singapore and Japan.

In Korea, EverEx is working to deepen clinical integration. Its digital therapeutic, MORA Cure, was recently designated as the country's first innovative medical device for musculoskeletal disorders. The company says it is now focused on linking the tool to electronic medical record systems and expanding distribution channels.

Investors pointed to the company’s proprietary AI model as a core asset behind the raise, according to Thursday's release. The model, trained on more than 700,000 musculoskeletal datasets and optimized for mobile use, has earned global recognition for its accuracy and reliability, the company said.

CEO Yoon Chan said the funding will help make personalized musculoskeletal rehab more accessible through AI, calling the space a high-potential area for digital health innovation.

EverEx operates under the MORA brand, which includes MORA Vu and MORA Fit for AI-based musculoskeletal assessment, MORA Care for workplace wellness, MORA Ex for remote rehab exercises, and MORA Cure as a prescription digital therapeutic.